| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PSG3 |
| Uniprot No | Q16557 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-428aa |
| 氨基酸序列 | QVTIEA EPTKVSKGKD VLLLVHNLPQ NLAGYIWYKG QMKDLYHYIT SYVVDGQIII YGPAYSGRET VYSNASLLIQ NVTREDAGSY TLHIVKRGDG TRGETGHFTF TLYLETPKPS ISSSNLYPRE DMEAVSLTCD PETPDASYLW WMNGQSLPMT HSLQLSKNKR TLFLFGVTKY TAGPYECEIR NPVSASRSDP VTLNLLPKLP KPYITINNLN PRENKDVLAF TCEPKSENYT YIWWLNGQSL PVSPRVKRPI ENRILILPSV TRNETGPYQC EIQDRYGGIR SYPVTLNVLY GPDLPRIYPS FTYYHSGENL YLSCFADSNP PAEYSWTING KFQLSGQKLF IPQITTKHSG LYACSVRNSA TGMESSKSMT VKVSAPSGTG HLPGLNPL |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PSG3(Pregnancy-Specific Glycoprotein 3)重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**: "Functional characterization of recombinant human pregnancy-specific glycoprotein 3"
**作者**: Smith A, et al.
**摘要**: 该研究成功表达并纯化了重组PSG3蛋白，发现其可通过与免疫细胞表面受体CD16结合，调节母胎界面Th1/Th2细胞因子平衡，支持妊娠免疫耐受。
2. **文献名称**: "Structural analysis of PSG3 reveals its role in trophoblast invasion"
**作者**: Chen L, et al.
**摘要**: 通过X射线晶体学解析PSG3重组蛋白的三维结构，发现其CUB结构域与细胞外基质蛋白互作，促进滋养层细胞迁移，为子痫前期发病机制提供新见解。
3. **文献名称**: "Recombinant PSG3 suppresses LPS-induced inflammation via TLR4/NF-κB pathway"
**作者**: Wang Y, et al.
**摘要**: 体外实验表明重组PSG3可抑制巨噬细胞TLR4信号通路，减少促炎因子TNF-α和IL-6分泌，提示其在炎症性疾病中的潜在治疗价值。
注：以上文献为示例性质，实际研究中建议通过PubMed或Web of Science查询最新研究。PSG3属于妊娠特异性糖蛋白家族，主要研究集中在生殖免疫学和肿瘤免疫治疗领域。
**Background of PSG3 Recombinant Protein**
Pregnancy-specific glycoproteins (PSGs), part of the carcinoembryonic antigen (CEA) family, are secreted proteins predominantly expressed in the placenta during pregnancy. Among these, PSG3 (Pregnancy-Specific Glycoprotein 3) plays critical roles in maternal-fetal interface regulation, immune modulation, and vascular remodeling. Structurally, PSG3 contains an N-terminal immunoglobulin variable (IgV)-like domain and multiple immunoglobulin constant (IgC)-like domains, facilitating interactions with receptors such as CD209 and heparan sulfate proteoglycans.
PSGs, including PSG3. are implicated in promoting trophoblast survival, enhancing angiogenesis, and suppressing maternal immune responses to support fetal tolerance. Dysregulation of PSG3 has been associated with pregnancy complications like preeclampsia and intrauterine growth restriction. Beyond reproductive biology, PSG3 is studied in oncology due to its ectopic expression in certain cancers, where it may influence tumor progression through immune evasion or stromal interactions.
Recombinant PSG3 is typically produced using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper glycosylation, essential for its functional activity. Purification methods often involve affinity chromatography, yielding high-purity proteins for research. As a tool, recombinant PSG3 aids in elucidating molecular mechanisms in placental development, immune tolerance, and cancer biology. It also holds therapeutic potential, such as in developing biomarkers for pregnancy disorders or immunomodulatory agents.
Current challenges include optimizing production scalability and understanding isoform-specific functions, as PSGs exhibit high sequence homology and functional redundancy. Ongoing research continues to explore PSG3's role in both physiological and pathological contexts, bridging gaps in reproductive medicine and oncology.
×
